Opendata, web and dolomites


Industrial-scale plant-based protein production in a cell-free platform

Total Cost €


EC-Contrib. €






Project "PEPPER" data sheet

The following table provides information about the project.


Organization address
postcode: 40231
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙391˙250 €
 EC max contribution 2˙373˙875 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LENIOBIO GMBH DE (DUSSELDORF) coordinator 2˙373˙875.00


 Project objective

The company LenioBio is a biotech company that develops and markets a novel, unique and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable and specifically targeting the substantial but underserved class of ‘difficult-to-express (DTE) proteins’.

LenioBio has developed a proprietary tobacco-based cell-free protein synthesis (CFPS) platform “ALiCE” with a higher yield (3 mg/ml) than any other eukaryotic cell-free system currently available (0.2 mg/ml) at a lower cost, while ensuring protein stability and activity. The goal of PEPPER is to bring LenioBio to a position of competitiveness and growth to be able to meet the current industrial demands of ‘difficult- to-produce’ proteins for various biotechnology sectors (e.g. pharmaceutical, and agricultural industries). To achieve this, LenioBio will scale-up the protein production capacity and yield to be able to produce proteins at an industrial scale using a semi- automated platform, while complying to GMP protocols and FDA/EMA regulations for biopharmaceuticals proteins. LenioBio’s mission is to offer a fully integrated protein production platform for pharmaceutical and biotechnology companies with the ability to scale along with our customers’ needs. LenioBio is developing the ALiCE® technology into the first eukaryotic cell-free production platform for any proteins.

LenioBio launched its first product as a protein expression kit in 2018 under the name ALiCE® (Almost Living Cell-free Expression). Due to its sustainable competitive advantages, already within nine months, 8 of the top 10 biopharma companies are customers, with more in the process of registering LenioBio as a vendor.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PEPPER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PEPPER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

GREEN WHS (2019)


Read More